Asthika Goonewardene
Stock Analyst at Truist Securities
(1.30)
# 3,510
Out of 4,944 analysts
99
Total ratings
36.96%
Success rate
-13.96%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Asthika Goonewardene
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GILD Gilead Sciences | Upgrades: Buy | $108 → $127 | $120.14 | +5.71% | 2 | Aug 8, 2025 | |
| EXEL Exelixis | Maintains: Buy | $56 → $49 | $38.49 | +27.31% | 11 | Jul 29, 2025 | |
| GMAB Genmab | Maintains: Buy | $45 → $46 | $22.67 | +102.91% | 15 | Jul 8, 2025 | |
| IGMS IGM Biosciences | Maintains: Hold | $2 → $1 | $1.27 | -21.26% | 9 | Jun 11, 2025 | |
| BNTX BioNTech SE | Reiterates: Buy | $151 → $155 | $112.78 | +37.44% | 3 | Jun 3, 2025 | |
| MRSN Mersana Therapeutics | Maintains: Buy | $225 → $250 | $6.81 | +3,571.07% | 4 | May 16, 2025 | |
| LEGN Legend Biotech | Maintains: Buy | $88 → $71 | $36.93 | +92.26% | 2 | May 14, 2025 | |
| ALLO Allogene Therapeutics | Maintains: Buy | $14 → $10 | $1.04 | +861.54% | 7 | May 14, 2025 | |
| AUTL Autolus Therapeutics | Maintains: Buy | $11 → $10 | $1.84 | +443.48% | 4 | Apr 1, 2025 | |
| IOVA Iovance Biotherapeutics | Maintains: Buy | $25 → $15 | $2.45 | +512.24% | 6 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $32 → $7 | $4.46 | +57.13% | 3 | Jan 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $35 | $26.87 | +30.26% | 1 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $87 → $136 | $70.90 | +91.82% | 5 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $15 | $0.77 | +1,843.01% | 6 | Aug 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $50 → $44 | $10.06 | +337.38% | 1 | Jun 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $69 → $88 | $67.22 | +30.91% | 2 | Jun 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5 → $4 | $1.49 | +168.46% | 5 | May 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 | $1.95 | +874.36% | 3 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $27 | $0.69 | +3,835.86% | 2 | Sep 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Hold | $120 | $26.87 | +346.59% | 1 | Apr 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $100 → $60 | $3.56 | +1,585.39% | 3 | Aug 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $228 → $180 | $5.19 | +3,368.21% | 4 | Aug 23, 2022 |
Gilead Sciences
Aug 8, 2025
Upgrades: Buy
Price Target: $108 → $127
Current: $120.14
Upside: +5.71%
Exelixis
Jul 29, 2025
Maintains: Buy
Price Target: $56 → $49
Current: $38.49
Upside: +27.31%
Genmab
Jul 8, 2025
Maintains: Buy
Price Target: $45 → $46
Current: $22.67
Upside: +102.91%
IGM Biosciences
Jun 11, 2025
Maintains: Hold
Price Target: $2 → $1
Current: $1.27
Upside: -21.26%
BioNTech SE
Jun 3, 2025
Reiterates: Buy
Price Target: $151 → $155
Current: $112.78
Upside: +37.44%
Mersana Therapeutics
May 16, 2025
Maintains: Buy
Price Target: $225 → $250
Current: $6.81
Upside: +3,571.07%
Legend Biotech
May 14, 2025
Maintains: Buy
Price Target: $88 → $71
Current: $36.93
Upside: +92.26%
Allogene Therapeutics
May 14, 2025
Maintains: Buy
Price Target: $14 → $10
Current: $1.04
Upside: +861.54%
Autolus Therapeutics
Apr 1, 2025
Maintains: Buy
Price Target: $11 → $10
Current: $1.84
Upside: +443.48%
Iovance Biotherapeutics
Mar 3, 2025
Maintains: Buy
Price Target: $25 → $15
Current: $2.45
Upside: +512.24%
Jan 30, 2025
Downgrades: Hold
Price Target: $32 → $7
Current: $4.46
Upside: +57.13%
Jan 8, 2025
Initiates: Buy
Price Target: $35
Current: $26.87
Upside: +30.26%
Nov 12, 2024
Maintains: Buy
Price Target: $87 → $136
Current: $70.90
Upside: +91.82%
Aug 16, 2024
Maintains: Buy
Price Target: $18 → $15
Current: $0.77
Upside: +1,843.01%
Jun 24, 2024
Maintains: Buy
Price Target: $50 → $44
Current: $10.06
Upside: +337.38%
Jun 4, 2024
Maintains: Buy
Price Target: $69 → $88
Current: $67.22
Upside: +30.91%
May 21, 2024
Maintains: Buy
Price Target: $5 → $4
Current: $1.49
Upside: +168.46%
May 16, 2024
Maintains: Buy
Price Target: $19
Current: $1.95
Upside: +874.36%
Sep 6, 2023
Reiterates: Buy
Price Target: $27
Current: $0.69
Upside: +3,835.86%
Apr 5, 2023
Reinstates: Hold
Price Target: $120
Current: $26.87
Upside: +346.59%
Aug 23, 2022
Maintains: Hold
Price Target: $100 → $60
Current: $3.56
Upside: +1,585.39%
Aug 23, 2022
Maintains: Buy
Price Target: $228 → $180
Current: $5.19
Upside: +3,368.21%